Compared to patients diagnosed with ER+/PR+/HER2− no special type invasive BC (NST, also known as invasive ductal carcinoma), those with ILC do not show additional benefit of adjuvant chemotherapy [6], tend to have larger tumors on presentation, an increased number of involved lymph nodes, and lower detection through mammographic screening compared to magnetic resonance imaging (MRI) [7]. The gene discussed is ERBB2; the disease is breast cancer.